Is your child with down syndrome hyperactive, inattentive, or impulsive?
If so, you may be interested in this new research study
The purpose of this research study is to learn more about how guanfacine immediate release (abbreviated as GIR) acts in the bodies of children with Down Syndrome (DS) who have hyperactivity/ADHD. GIR is a drug that is given to children by their health care providers to treat hyperactivity and Attention Deficit Hyperactivity Disorder (ADHD). By studying this drug, we hope to find the safest and most effective dose in children with DS. This is important, because we do not have enough information to know if the doses of GIR used in children with DS who have hyperactivity/ impulsivity or inattention are safe or effective.
If you decide to participate in the study, some tests like ECG and blood draw will be done to see if you are eligible for this study. The study doctor will determine if you may qualify for the study. Taking part in this study will involve regular visits to the study center. The study will last approximately up to 102 days, and you will need to visit the study center up to 3 times.
You will receive all study-required evaluations and procedures at no cost. We will pay you $50 for each completed onsite visit for this study.
For more information, contact the study team:
Dr. Maria Stanley, MD, Department of Pediatrics, University of Wisconsin
600 Highland Avenue, Madison, WI 53792, Tel: 608-263-3301
PI: Dr. Maria Stanley, MD
Keywords: Down Syndrome, Attention Deficit / Hyperactivity Disorder Studies